ODIN Forvaltning
1
12M
1
0.03
- Areas of investment
Summary
In 1990 was created ODIN Forvaltning, which is appeared as Corporate Investor. The main office of represented Corporate Investor is situated in the Oslo. The company was established in Europe in Norway.
Among the most successful fund investment fields, there are Clinical Trials, Biotechnology. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Sangart. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.
The typical case for the fund is to invest in rounds with 1 participant. In the next rounds fund is usually obtained by Leucadia National.
The top activity for fund was in 2003. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in less than 2 deals every year.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Rounds per year
- 0.03
- Investments by industry
- Clinical Trials (1)
- Therapeutics (1)
- Biotechnology (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2003
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 23
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.